GFAT1/HBP/O-GlcNAcylation Axis Regulates β-Catenin Activity to Promote Pancreatic Cancer Aggressiveness

Table 1

Pan-cancer analysis of the prognostic value of the hexosamine biosynthetic pathway.

Tumor	High ()	Low ()	HR	value	Tumor	High ()	Low ()	HR	value
ACC	38	38	2.4	0.023	LUSC	241	241	1.0	0.86
BLCA	201	201	1.3	0.13	MESO	41	41	0.95	0.83
BRCA	535	535	1.5	0.007	OV	212	212	1.2	0.17
CESC	146	146	1.3	0.25	PAAD	89	89	1.6	0.02
CHOL	18	18	0.72	0.5	PCPG	91	91	2.4	0.32
COAD	135	135	1.0	0.87	PRAD	246	246	0.77	0.69
DLBC	23	23	1.0	1.0	READ	46	46	1.1	0.87
ESCA	91	91	1.1	0.74	SARC	131	131	1.0	0.92
GBM	81	81	1.3	0.12	SKCM	229	229	1.0	0.84
HNSC	259	259	0.99	0.97	STAD	192	192	1.1	0.7
KICH	32	32	8.5	0.015	TGCT	68	68	1.9	0.61
KIRC	258	258	0.67	0.011	THCA	255	255	1.5	0.41
KIRP	141	141	0.99	0.97	THYM	59	59	1.8	0.26
LAML	53	53	1.1	0.82	UCEC	86	86	1.0	0.92
LGG	257	257	1.8	0.002	UCS	28	28	0.81	0.53
LIHC	182	182	1.6	0.012	UVM	39	39	2.1	0.092
LUAD	239	239	1.4	0.022

High and low indicate tumor samples with higher and lower HBP activity, respectively. HR is hazard ratio; the value was a comparison of survival time between tumor samples with higher and lower HBP activity by the log-rank test. ACC: adrenocortical carcinoma; BLCA: Bladder Urothelial Carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: cholangiocarcinoma; COAD: colon adenocarcinoma; DLBC: Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; ESCA: esophageal carcinoma; GBM: glioblastoma multiforme; HNSC: head and neck squamous cell carcinoma; KICH: kidney chromophobe; KIRC: kidney renal clear cell carcinoma; KIRP: kidney renal papillary cell carcinoma; LAML: Acute Myeloid Leukemia; LGG: Brain Lower Grade Glioma; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; MESO: mesothelioma; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PCPG: Pheochromocytoma and Paraganglioma; PRAD: prostate adenocarcinoma; READ: rectum adenocarcinoma; SARC: sarcoma; SKCM: Skin Cutaneous Melanoma; STAD: stomach adenocarcinoma; TGCT: Testicular Germ Cell Tumors; THCA: thyroid carcinoma; THYM: thymoma; UCEC: Uterine Corpus Endometrial Carcinoma; UCS: Uterine Carcinosarcoma; UVM: Uveal Melanoma.